Connect Biopharma Holdings Limited (CNTB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Connect Biopharma Holdings Limited (NASDAQ: CNTB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.78 (-3.13% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNTB ranks #914 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYPD (Hyperion DeFi Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $49.7M) and CTOR (Citius Oncology Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M). Among the 5-stock peer group, CNTB leads on earnings multiple (N/A) while CNTB leads on capital efficiency (-35.0% ROIC).
Per CNTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835268), Connect Biopharma Holdings Limited generated $64.0K in revenue (-99.8% YoY), -$55.5M in net income, and -$51.6M in free cash flow against $56.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.2 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CNTB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.82) forces dealer call-delta covering toward $4.01.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Connect Biopharma Holdings Limited (CNTB) dropped -3.13% to $0.78, trading at 2% of its 52-week range ($0.73 – $3.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren
Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company
Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the F
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations thro
Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over
Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Inve
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CNTB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CNTB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Connect Biopharma Holdings Limited (CNTB) ranks #914 by composite RQD confidence (26/100, grade E) and #744 by equity capitalization ($50.5M). Within this direct 5-issuer industry benchmark cohort, CNTB leads on earnings valuation at N/A trailing P/E, while CNTB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with CNTB at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CNTB
ACTIVE
Connect Biopharma Holdings Limited | E | 26/100 | — | — | -35.0% | -3.13% | $50.5M | Benchmark Subject |
| HYPD Hyperion DeFi Inc. | D- | 38/100 | — | 62.7% | -35.0% | -7.76% | $49.7M | /hypd-vs-cntb → |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | +7.24% | $51.5M | /ctor-vs-cntb → |
| IBIO iBio Inc. | E | 23/100 | — | — | -35.0% | +4.06% | $49.4M | /ibio-vs-cntb → |
| GANX Gain Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | 0.00% | $49.3M | /ganx-vs-cntb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Connect Biopharma Holdings Limited (CNTB) reported GAAP revenue of $64.0K (-99.8% vs. FY2024 revenue of $26.0M , and -100.0% cumulative change since FY2023) , GAAP net income of -$55.5M, operating cash flow of -$51.2M, and free cash flow of -$51.6M (-112.0% YoY). On the balance sheet, CNTB closed FY2025 with $56.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $64.0K | -$55.5M | -$51.2M | -$51.6M | $56.1M | — |
| FY2024 (FY) | 2024-12-31 | $26.0M | -$15.6M | -$23.6M | -$24.4M | $101.3M | — |
| FY2023 (FY) | 2023-12-31 | $193.4M | -$62.1M | -$47.7M | -$47.7M | — | — |
As of 2026-11-03, Connect Biopharma Holdings Limited (NASDAQ: CNTB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.78 (-3.13% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNTB ranks #914 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYPD (Hyperion DeFi Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $49.7M) and CTOR (Citius Oncology Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M). Among the 5-stock peer group, CNTB leads on earnings multiple (N/A) while CNTB leads on capital efficiency (-35.0% ROIC).
Per CNTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835268), Connect Biopharma Holdings Limited generated $64.0K in revenue (-99.8% YoY), -$55.5M in net income, and -$51.6M in free cash flow against $56.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CNTB last traded at $0.78 (-3.13% on volume of 523,405 shares), positioning the stock -41.35% below its 50-day simple moving average ($1.33) and -64.38% below its 200-day simple moving average ($2.19). Across its 52-week range of $0.73 to $3.82, CNTB sits at the 1.6% percentile with a 14-day RSI of 33.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.88).
CNTB scores 35 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 7 / 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 12 / 20 (institutional accumulation and options positioning), the strongest pillar but still below mid-range. Insider Conviction scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), the weakest pillar, suggesting little insider-side conviction in the data. Macro Regime Fit scores 8 / 20 (Beta 1.0; sector sensitivity), a neutral-to-weak read on how the stock sits within its sector regime. Forensic Balance Sheet scores 5 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting weak forensic financial health signals.
For a prospective investor evaluating the stock today, the upside case rests on the institutional flow pillar and the moderate leverage ratio, while the valuation tradeoff is severe: the stock trades at $0.8 with a $52.6M market cap against operating losses that the financial data shows exceed reported revenue in the most recent period. The ratings imply that a buyer is underwriting a turnaround in cash generation that the current filings do not yet demonstrate.
Connect Biopharma Holdings Limited (CNTB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.1B.
And market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%, with FCF yield at 0%. The Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash declined from $78.2M in FY 2024 to $38.3M in FY 2025 alongside continued negative free cash flow.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CNTB carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Connect Biopharma Holdings Limited (CNTB) • Click "Debate This Headline" to argue it in the Roar Pit below
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tren
Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.
Connect Biopharma (NASDAQ:CNTB) reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company
Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the F
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations thro
The street is overcomplicating Connect Biopharma Holdings Limited (CNTB). Institutional accumulation and options positioning score 12 / 20, the strongest RQD pillar, while debt-to-equity of 0.5 indicates moderate leverage.. With an RQD score of 26/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.86.
@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Connect Biopharma Holdings Limited, but the stock at $0.80 is a different story. FY 2025 operating loss of -$58.1M exceeds $0.1M revenue, with ROIC at -35%, FCF yield at 0%, and cash falling from $78.2M to $38.3M.. FCF yield is 0.0% and RQD sits at 26/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).